1 day Ago By ABMN Staff
Clene ( NASDAQ:CLNN – Get Free Report ) ‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They currently have a $31.00 price objective on the stock.
HC Wainwright’s target price would indicate a potential upside of 486.01% from the stock’s current price. CLNN has been the subject of a number of other research reports.
Canaccord Genuity Group restated a “buy” rating and issued a $94.00 price objective on shares of Clene in a research report on Tuesday, August 6th. EF Hutton Acquisition Co.
I upgraded Clene to a “strong-buy” rating in a report on Tuesday, September 10th. Finally, Benchmark reaffirmed a “buy” rating and set a $100.00 price target on shares of Clene in a research report on Thursday, May 23rd.
Read Our Latest Report on Clene Clene Stock Down 5.4 % Clene ( NASDAQ:CLNN – Get Free Report ) last released its earnings results on Wednesday, August 7th. The company reported ($1.
06) earnings per share for the quarter, beating the consensus estimate of ($1.60) by $0.54.
The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.10 million.
Clene had a negative return on equity of 315.97% and a negative net margin of 6,890.50%.
Equities analysts expect that Clene will post -5.26 EPS for the current year. Hedge Funds Weigh In On Clene An institutional investor recently raised its position in Clene stock.
Csenge Advisory Group raised its position in Clene Inc. ( NASDAQ:CLNN – Free Report ) by 131.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC).
The institutional investor owned 269,600 shares of the company’s stock after buying an additional 153,000 shares during the quarter. Csenge Advisory Group owned 0.21% of Clene worth $96,000 at the end of the most recent reporting period.
23.28% of the stock is owned by hedge funds and other institutional investors. About Clene ( Get Free Report ) Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. See Also Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter .
.
